Coeptis Therapeutics Holdings, Inc. announced a private placement of 4,300 Series A convertible preferred shares at a purchase price of $1,000 per share for gross proceeds of $4,300,000 led by new investor CJC Investment Trust on June 14, 2024. The Series A preferred share is convertible into shares at a price of $0.40 per share, subject to limitations. The company received funding pursuant to exemption provided under Regulation D. The transaction included participation from 7 investors.